ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AEZS Stock Price » AEZS Stock News

Aeterna Zentaris Share News

 Aeterna Zentaris (mm) Stock Price
AEZS Stock Price
 Aeterna Zentaris (mm) Stock Chart
AEZS Stock Chart
 Aeterna Zentaris (mm) Stock News
AEZS Stock News
 Aeterna Zentaris (mm) Company Information
AEZS Company Information
 Aeterna Zentaris (mm) Stock Trades
AEZS Stock Trades

FDA Fast Tracks Keryx Immune-System Cancer Drug; Shares Rise

DOW JONES NEWSWIRES Keryx Biopharmaceuticals Inc.'s (KERX) experimental drug to treat a kind of cancer in white blood cells received fast-track status from the Food and Drug Administration. Shares were up 13% premarket at $3. The stock has soared this year due to progress on its renal-disease drug, rising more than tenfold. U.S.-traded shares in Keryx's Canadian partner Aeterna Zentaris Inc. (AEZ.T, AEZS) were also up 10% at $1.10. Keryx expects to start late-stage trials on KRX-0401, a potentially first-in-class, oral anti-cancer agent, later this month under a special protocol assessment with the FDA. In September, the agency also granted the treatment orphan status, which is reserved for new therapies for diseases or conditions that affect fewer than 200,000 people in the country. It gives drug developers seven years of market exclusivity. The treatment was in-licensed by Keryx from Aeterna in the U.S., Canada and Mexico, while Aeterna holds rights elsewhere. In September, Keryx said its renal-disease drug Zerenex was well tolerated and safe for long-term use in its first long-term trial. Multiple myeloma, also known as Kahler's disease, is a cancer in white blood cells, a integral part of the body's immune system. The FDA's fast-track designation is meant to accelerate the availability of new drugs that could provide a therapy for patients with serious diseases where no other treatment exists or where the existing therapy may be inferior. -By Joan E. Solsman, Dow Jones Newswires; 212-416-2291; joan.solsman@dowjones.com

Stock News for Aeterna Zentaris (AEZS)
DateTimeHeadline
08/13/201516:39:11Report of Foreign Issuer (6-k)
08/13/201516:38:19Report of Foreign Issuer (6-k)
08/13/201516:15:00Aeterna Zentaris annonce ses résultats financiers et d'exploitation...
08/13/201516:15:00Aeterna Zentaris Reports Second Quarter Financial and Operating...
08/13/201516:15:00Aeterna Zentaris Reports Second Quarter Financial and Operating...
08/11/201507:30:00Aeterna Zentaris : 2e analyse intérimaire de l'étude ZoptEC d...
08/11/201507:30:00Aeterna Zentaris Announces Data and Safety Monitoring Board Scheduled...
08/11/201507:30:00Aeterna Zentaris Announces Data and Safety Monitoring Board Scheduled...
08/06/201507:30:00Aeterna Zentaris dévoilera ses résultats financiers et d'exploitation d...
08/06/201507:30:00Aeterna Zentaris to Announce Second Quarter 2015 Financial and...
08/06/201507:30:00Aeterna Zentaris to Announce Second Quarter 2015 Financial and...
08/04/201507:30:00Aeterna Zentaris fera une présentation à la Canaccord Genuity 3...
08/04/201507:30:00Aeterna Zentaris to Present at Upcoming Canaccord Genuity 35th...
08/04/201507:30:00Aeterna Zentaris to Present at Upcoming Canaccord Genuity 35th...
07/29/201507:30:00Aeterna Zentaris annonce l'optimisation de composés inhibiteurs...
07/29/201507:30:00Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds...
07/29/201507:30:00Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds...
07/28/201507:30:00Aeterna Zentaris accorde une option pour développer et commercialiser...
07/28/201507:30:00Aeterna Zentaris Grants Option to Develop and Commercialize Oral...
07/28/201507:30:00Aeterna Zentaris Grants Option to Develop and Commercialize Oral...

Aeterna Zentaris and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad